New drug LM-108 targets Hard-to-Treat cancers in early trial
NCT ID NCT05518045
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tests an experimental drug called LM-108 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to help the immune system fight cancer. The trial involves about 392 adults and aims to find safe doses and see if the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.